In the Phase 3 ATTAIN-1 clinical trial, orforglipron, an experimental oral GLP-1 receptor agonist from Eli Lilly, showed significant weight loss efficacy. Over the course of 72 weeks, participants lost an average of up to 27.3 pounds (12.4% body weight decrease). Only 2.2 pounds (0.9%) of weight was lost at the highest dose of orforglipron (36 mg), which performed noticeably better than the placebo.
In all three tested doses, the trial’s primary endpoint—a superior reduction in body weight when compared to a placebo was successfully achieved. According to important secondary analyses, 39.6% of individuals who took the highest dose lost at least 15% of their body weight, and 59.6% of people lost at least 10%. The effectiveness estimate, which shows weight loss outcomes assuming all individuals remained on treatment, was used to obtain these results.
Read More: Eli Lilly Reports Strong Q2 2025 Financial Results with 38% Revenue Growth
Study Design and Population
In the United States, Brazil, China, India, Japan, South Korea, Puerto Rico, Slovakia, Spain, and Taiwan, ATTAIN-1 recruited 3,127 adults who were overweight or obese and had weight-related medical problems but no diabetes. The average baseline weight of the participants was 227.5 pounds (103.2 kg), and their average BMI was 37.0.
Using a randomized, double-blind, placebo-controlled design, subjects were assigned in a 3:3:3:4 ratio to receive either a placebo, orforglipron 6 mg, 12 mg, or 36 mg. To get to their designated maintenance dose, each participant started with a 1 mg starting dose and experienced step-by-step dose escalation every four weeks.
Read More: Eli Lilly Reported a Very Strong Start to 2025, Characterized by Significant Revenue Growth
Dosing and Administration
Orforglipron, a once-daily oral GLP-1 receptor agonist that is not meal- or water-dependent, represents a major breakthrough. By target dose, the dose escalation protocol changed:
- 6 mg group: Increased in increments of 1 mg and 3 mg.
- Escalated through steps of 1 mg, 3 mg, and 6 mg for the 12 mg group.
- The 36 mg group was increased in stages of 1 mg, 3 mg, 6 mg, 12 mg, and 24 mg.
Comprehensive Efficacy Results
| Dose | Weight Loss (%) | Weight Loss (lbs) | ≥10% Weight Loss | ≥15% Weight Loss |
|---|---|---|---|---|
| Orforglipron 6 mg | -7.8% | -17.6 lbs | 35.9% | 16.5% |
| Orforglipron 12 mg | -9.3% | -20.7 lbs | 45.1% | 24.0% |
| Orforglipron 36 mg | -12.4% | -27.3 lbs | 59.6% | 39.6% |
| Placebo | -0.9% | -2.2 lbs | 8.6% | 3.6% |
Results from the treatment-regimen estimand, which takes into consideration actual adherence patterns, were similarly strong.
| Dose | Weight Loss (%) | Weight Loss (lbs) | ≥10% Weight Loss | ≥15% Weight Loss |
|---|---|---|---|---|
| Orforglipron 6 mg | -7.5% | -17.2 lbs | 33.3% | 15.1% |
| Orforglipron 12 mg | -8.4% | -19.0 lbs | 40.0% | 20.3% |
| Orforglipron 36 mg | -11.2% | -25.0 lbs | 54.6% | 36.0% |
| Placebo | -2.1% | -5.3 lbs | 12.9% | 5.9% |
Orforglipron’s safety profile was in line with that of well-established GLP-1 receptor agonist treatments; the most frequent adverse reactions were gastrointestinal ones, which were typically mild to moderate in intensity.
Cardiovascular Risk Factor Improvements
In addition to helping people lose weight, orforglipron showed positive effects on a number of cardiovascular risk indicators. Systolic blood pressure, triglycerides, and non-HDL cholesterol all decreased in pooled analysis across all doses. High-sensitivity C-reactive protein (hsCRP) levels were reduced by 47.7% at the maximum dose in a pre-specified exploratory analysis, suggesting a reduction in systemic inflammation.
Regulatory Timeline and Market Launch
By the end of 2025, Lilly intends to submit orforglipron to international regulatory bodies in light of these promising Phase 3 results. In order to guarantee sufficient supply capacity to satisfy projected demand upon possible approval, the company is concurrently making significant expenditures.
Last Modified:
